Retatrutide Phase 3 Results: What the New TRIUMPH-2 Data Show
Updated October 1, 2026. Retatrutide has moved back into the spotlight after Eli Lilly released detailed Phase 3 TRIUMPH-2 results in adults with obesity or overweight and type 2 diabetes. The investigational once-weekly medicine targets three hormone receptors—GIP, GLP-1 and glucagon—making it one of the most closely watched next-generation metabolic therapies in development.
Important: Retatrutide is investigational and is not approved for routine clinical use. The information below summarizes published and company-reported clinical research and should not be interpreted as medical advice or as a recommendation to obtain or use an unapproved product.
What are the latest retatrutide Phase 3 results?
In detailed TRIUMPH-2 results released September 29, 2026, Eli Lilly reported that participants receiving retatrutide 12 mg lost an average of 49.6 lb (22.5 kg), or 20.8% of body weight, over 80 weeks using the efficacy estimand. Among participants starting with a BMI of 35 or higher, average weight reduction reached 23.4% at the 12 mg dose.
Lilly also reported A1C reductions of up to 1.6 percentage points. Up to 40% of participants achieved an A1C below 5.7%, and more than half of participants receiving 12 mg no longer met BMI criteria for obesity by the end of the trial.
The findings were presented at the 2026 Annual Meeting of the European Association for the Study of Diabetes (EASD). TRIUMPH-2 was sponsored by Eli Lilly.
How does retatrutide work?
Retatrutide is designed to activate three receptors involved in metabolic regulation: GIP, GLP-1 and glucagon. This triple-receptor mechanism is the main reason researchers are interested in whether retatrutide can produce meaningful effects on body weight, blood glucose and broader cardiometabolic measures.
GLP-1 signaling is associated with appetite and glucose regulation. GIP also participates in glucose-dependent insulin signaling, while glucagon has roles in hepatic glucose regulation and energy metabolism. Retatrutide combines activity across all three pathways in a single investigational molecule.
How is retatrutide different from semaglutide and tirzepatide?
The key difference is receptor targeting. Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual GIP/GLP-1 receptor agonist. Retatrutide is designed to activate GIP, GLP-1 and glucagon receptors.
That mechanistic difference does not, by itself, establish clinical superiority. Cross-trial comparisons can be misleading because studies differ in participant characteristics, duration, dose escalation, background therapy and statistical methods. Head-to-head randomized trials offer stronger evidence than comparing headline percentages from separate programs.
Why TRIUMPH-2 matters
TRIUMPH-2 is especially relevant because it studied people with obesity or overweight and type 2 diabetes—a population in which weight reduction can be more difficult than in people without diabetes. The trial therefore provides information about both weight management and glycemic control in the same population.
The broader clinical question is also evolving. Percentage weight loss remains important, but clinicians and researchers increasingly examine A1C, waist circumference, blood pressure, blood lipids, inflammation markers, body composition and longer-term cardiovascular and kidney outcomes. Those endpoints help determine whether a therapy’s metabolic effects translate into meaningful health benefits.
What do earlier Phase 3 studies tell us?
Retatrutide’s Phase 3 program extends beyond TRIUMPH-2. In the TRANSCEND-T2D-1 trial published in The Lancet in June 2026, adults with type 2 diabetes inadequately controlled by diet and exercise received retatrutide or placebo for 40 weeks. Retatrutide reduced A1C and body weight across the studied doses, adding peer-reviewed Phase 3 evidence to the development program.
Lilly is also studying retatrutide in additional obesity, diabetes and cardiometabolic outcome trials. These ongoing studies are important because short- and medium-term changes in weight and laboratory markers do not answer every question about long-term safety and clinical outcomes.
What are the side effects and limitations?
Gastrointestinal adverse events—including nausea, diarrhea, vomiting and constipation—have been among the most commonly reported side effects in clinical studies of retatrutide and related incretin-based therapies. The frequency and severity of adverse events can vary by dose and during dose escalation.
Other limitations matter when interpreting the headlines. TRIUMPH-2 was industry sponsored. The highest reported weight-loss number reflects a specific statistical estimand. Trial populations do not perfectly represent every person who may eventually receive treatment, and longer-term outcome data remain important.
Is retatrutide approved?
No. Retatrutide remains investigational as of October 1, 2026. It should not be confused with approved medicines such as semaglutide- or tirzepatide-based products. Regulatory agencies must independently review a medicine’s manufacturing, efficacy and safety evidence before approving it for a specific indication.
Is retatrutide approved in Canada?
No. As of October 2026, retatrutide remains investigational and is not approved by Health Canada for routine human use. Canadian clinical trials involving retatrutide are authorized and listed through Health Canada’s Canadian Clinical Trial Search Portal, but authorization to conduct a clinical trial is different from regulatory approval to market a medicine.
For people searching for retatrutide Canada or retatrutide clinical trials Canada, this distinction is important: participation in Canadian Phase 3 and Phase 3b research does not mean the drug has received commercial approval. Health Canada’s portal lists retatrutide studies examining obesity, type 2 diabetes, weight-maintenance strategies, and cardiovascular and kidney outcomes.
When could retatrutide become available?
Lilly has continued to advance the Phase 3 development program and has discussed future regulatory submissions. Exact approval and launch timelines remain uncertain until regulators complete their reviews. Clinical-trial success does not guarantee approval.
What should researchers and patients watch next?
Key questions include how retatrutide performs in head-to-head studies, whether its metabolic improvements translate into cardiovascular or kidney benefits, how tolerability affects long-term adherence, and whether the triple-agonist mechanism provides advantages that remain meaningful outside tightly controlled clinical trials.
Frequently asked questions
What is retatrutide?
Retatrutide is an investigational once-weekly triple hormone receptor agonist developed by Eli Lilly. It targets GIP, GLP-1 and glucagon receptors.
How much weight did participants lose in TRIUMPH-2?
Lilly reported average weight loss of up to 20.8% over 80 weeks at the 12 mg dose using the efficacy estimand. Results varied by dose, baseline characteristics and statistical approach.
Is retatrutide stronger than tirzepatide?
That cannot be concluded reliably from separate trials. Retatrutide and tirzepatide have different receptor profiles, but properly designed head-to-head studies are more informative than comparing percentages across different clinical programs.
Is retatrutide a GLP-1 drug?
Retatrutide includes GLP-1 receptor activity, but it also activates GIP and glucagon receptors. For that reason it is usually described as a triple GIP/GLP-1/glucagon receptor agonist.
Is retatrutide approved by the FDA?
No. As of October 1, 2026, retatrutide remains investigational and has not completed the regulatory process required for routine prescription use.
Is retatrutide approved in Canada?
No. As of October 2026, retatrutide is not approved by Health Canada for routine human use. Canada does have authorized retatrutide clinical trials, but clinical-trial authorization is not the same as marketing approval.
Are there retatrutide Phase 3 trials in Canada?
Yes. Health Canada’s Canadian Clinical Trial Search Portal lists multiple retatrutide Phase 3 and Phase 3b studies. These studies contribute to the clinical evidence regulators may eventually review, but they do not establish approval or commercial availability.
Sources
Eli Lilly and Company: Detailed TRIUMPH-2 Phase 3 results, September 29, 2026.
The Lancet: TRANSCEND-T2D-1 randomized Phase 3 trial.
American Diabetes Association: Phase 3 retatrutide research overview from ADA 2026.